Teva is “cautiously optimistic” it is moving towards a US-wide settlement over allegations the firm helped fuel the opioid epidemic, with the potential to strike a deal “within the coming year,” as the company’s CEO Kåre Schultz speculated that the Israeli firm’s inability to offer more cash as part of any deal had led lawyers to prioritize the other parties.
Last week, Johnson & Johnson proposed to pay up to $5bn over nine years and the three largest US distributors...






